BioSpace News Archive

PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ending September 30, 2023.

CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the third quarter of 2023.

TransCode Therapeutics, Inc., an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced the commencement of an underwritten public offering of shares of its common stock.

Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, will report financial results for the third quarter 2023 after market close on Monday, November 6, 2023.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2023.

27.9 million men and women in the United States will suffer from kidney stones during their lifetime (U.S. Department of Health and Human Services).

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and six months ended September 30, 2023.

Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced positive results from a combined analysis of six-month follow-up data from the three RADIANCE global clinical studies evaluating the Paradise™ Ultrasound Renal Denervation (uRDN) system as a treatment for hypertension.

Bausch Health Companies Inc. today Looking Forward, the television ad campaign for APLENZIN (bupropion hydrobromide) extended-release tablets for individuals diagnosed with seasonal affective disorder (SAD), a type of depression that follows a seasonal pattern.

Viridian Therapeutics, Inc. and Ypsomed AG (SIX: YPSN), the leading developer and manufacturer of injection and infusion systems for self-medication have signed a supply agreement for Ypsomed’s customizable YpsoMate 2.25 autoinjector pen device with a fill volume of 2.0 milliliters.